Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    TopAbstracts in Diabetes 10/07/2008 - (DGNews)
    Depression Linked to Higher Death Rates From All Causes Among Elderly With Diabetes - (DGNews)
    TopAbstracts in Diabetes 09/30/2008 - (DGNews)
    Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial - (BMJ)
    Candesartan Increases Regression of Retinopathy in Type 2 Diabetes, Reduces Incidence in Type 1 Diabetes - (DGNews)

    News archive

     Recent webcasts/CME - Diabetes
      Hyperglycemia in Acute Coronary Syndromes
      Impact of Insulin Resistance on Cardiometabolic Risk
      Reducing Cardiovascular Morbidity and Mortality Through RAAS Modulation: New Trial Data
      Clinical Imperatives for Treating Patients with Diabetes
      Cardiometabolic Risk and Risk Management

      Webcasts/CME archive

       Recent cases - Diabetes
        Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report
        Diabetic Fetopathy Associated with Bilateral Adrenal Hyperplasia and Ambiguous Genitalia: A Case Report
        Somatostatinoma: A Rare Cause of Diabetic Ketosis
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Ruboxistaurin May Improve Diabetic Nephropathy: Presented at ADA

        By Jill Stein

        SAN DIEGO, CA -- June 14, 2005 -- The investigational compound ruboxistaurin mesylate appears to significantly decrease albuminuria in patients with type 2 diabetes and nephropathy on stable doses of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or both.

        These findings, from a year-long phase 2 trial, were presented here on June 13th at the American Diabetes Association's 65th Annual Scientific Sessions (ADA).

        Ruboxistaurin is a selective inhibitor of protein kinase C beta, an enzyme that has been implicated in the underlying process of microvascular damage caused by diabetes. In addition to diabetic nephropathy, the compound is being evaluated for potential use in the treatment of diabetic peripheral neuropathy and diabetic retinopathy.

        Katherine Tuttle, MD, director of research, Heart Institute of Spokane, Spokane, Washington, presented the results based on a study of 123 patients who were randomized to ruboxistaurin 32 mg/day or placebo. Patients continued treatment with these agents throughout the trial.

        In experimental studies, ruboxistaurin had been shown to improve renal disease, Dr. Tuttle said.

        In Dr. Tuttle's study, all subjects had persistent albuminuria despite treatment with stable doses of ACE inhibitors, ARBs, or both for at least 6 months before the start of the trial. Persistent albuminuria was defined as a urinary albumin/creatinine ratio (ACR) of 200 to 2000 mg/g.

        After 1 year, ACR decreased significantly by 24% from baseline (P =.02) but the 9% decrease in the placebo group did not reach significance (P =.33). The decrease in albuminuria in the ruboxistaurin group was apparent after 1 month of treatment and remained consistent throughout the trial.

        Glomerular filtration rate (GFR) decreased by 4.8 mL/min/year (P =.009) in placebo-treated subjects over 1 year but did not decrease significantly in the ruboxistaurin group (-2.5 mL/min/year, P =.185).

        Dr. Tuttle emphasized that while comparisons for both ACR and GFR were not different between the treatment groups, this trial was not designed to determine such a difference and the power for either analysis was less than 20%.

        Ruboxistaurin and placebo groups were similar with respect to adverse effects, although more patients in the placebo group had hypertensive episodes requiring intervention.

        Overall, ruboxistaurin was well tolerated, however the small sample size and short follow-up period rule out definitive conclusions about safety, Dr. Tuttle said.

        Overall, the results suggest that ruboxistaurin may improve upon established therapies for diabetic nephropathy, she concluded.

        The study was sponsored by Eli Lilly and Company, Indianapolis, Indiana.


        [Presentation title: Effect of Ruboxistaurin on Albuminuria and GFR in Persons With Type 2 Diabetes and Nephropathy. Abstract 223-OR]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send